Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion
Objective: To evaluate whether treatment with foslevodopa/foscarbidopa (LDP/CDP), a continuous (24‑hour/day) subcutaneous infusion of carbidopa/levodopa prodrugs, improves motor fluctuations and quality of life (QoL) in…Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset
Objective: To determine the effect of the serotonin 2A/2C (5-HT2A/2C) receptor inverse agonist nelotanserin on dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: Nelotanserin is a…What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)
Objective: To investigate correlations between plasma levels of 24(S)-Hydroxycholesterol (24[S]-HC) and cognitive performance in participants with Huntington’s disease (HD) using data from ENROLL-HD. Background: HD…Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…Efficacy of perampanel in paroxysmal kinesigenic dyskinesia
Objective: To explore the efficacy and safety of perampanel in the treatment of paroxysmal kinesigenic dyskinesia (PKD) Background: Perampanel is a new type of antiepileptic…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…A Retrospective Review of Amantadine in Progressive Supranuclear Palsy
Objective: To determine the efficacy and tolerability of amantadine in Progressive supranuclear palsy (PSP). Background: PSP is one of the most common atypical parkinsonian disorders,…Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson’s Disease Based on Network Pharmacology and Molecular Docking
Objective: Based on the method of network pharmacology, this paper discusses the potential effects and mechanisms of SGD in the treatment of pain in PD. Background:…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 32
- Next Page »